Full View

Trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer: a retrospective study at a tertiary oncology center

AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - academic.oup.com
Abstract Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …
被引用次数：12 相关文章

Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.

AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - europepmc.org
Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with
refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist …

Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center

AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with
refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist …

Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center

AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - Wiley Online Library
Abstract Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …

Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.

AK PATEL, R ABHYANKAR, LK BRAIS… - …, 2021 - search.ebscohost.com
Abstract Background. Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …
[HTML] nih.gov

[HTML][HTML] Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center

AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - ncbi.nlm.nih.gov
Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with
refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist …